Medicare Part D drugs starting with A
208 drugs start with A; 92 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Austedo in 2024: $1.7 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with A?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Abacavir | 100% | Tier 4 | $3 million |
| Abacavir / lamivudine | 100% | Tier 4 | $6 million |
| Abigale (estradiol / norethindrone acetate) | 72.7% | Tier 4 | no 2024 match |
| Abigale Lo (estradiol / norethindrone acetate) | 69.8% | Tier 1 | no 2024 match |
| Abilify (aripiprazole) | 100% | Tier 5 | $7 million |
| Abiraterone acetate | 99.6% | Tier 5 | $693 million |
| Abirtega (abiraterone acetate) | 91.8% | Tier 4 | no 2024 match |
| Abrysvo (RSV vaccine) | 100% | Tier 1 | $468 million |
| Acamprosate calcium | 100% | Tier 4 | $6 million |
| Acarbose | 100% | Tier 2 | $6 million |
| Accutane (isotretinoin) | 88.3% | Tier 4 | $70 thousand |
| Acebutolol | 99.3% | Tier 2 | $4 million |
| Acetaminophen / butalbital | 5% | Tier 2 | $2 million |
| Acetaminophen / butalbital / caffeine | 54.2% | Tier 2 | $23 million |
| Acetaminophen / butalbital / caffeine / codeine phosphate | 5.8% | Tier 2 | $4 million |
| Acetaminophen / codeine phosphate | 100% | Tier 2 | $33 million |
| Acetaminophen / hydrocodone bitartrate | 100% | Tier 3 | $387 million |
| Acetaminophen / oxycodone hydrochloride | 100% | Tier 3 | $243 million |
| Acetaminophen / tramadol hydrochloride | 66.3% | Tier 2 | $4 million |
| Acetazolamide | 100% | Tier 2 | $15 million |
| Acetic acid | 97.7% | Tier 2 | $2 million |
| Acetic acid / hydrocortisone | 87.5% | Tier 4 | $3 million |
| Acetylcysteine | 97.8% | Tier 2 | $2 million |
| Acitretin | 100% | Tier 4 | $14 million |
| Actemra (tocilizumab) | 8.4% | Tier 5 | $132 million |
| Acthar (corticotropin) | 2.9% | Tier 5 | $360 million |
| ActHIB (Hib vaccine) | 100% | Tier 1 | $66 thousand |
| Actimmune (interferon gamma-1b) | 100% | Tier 5 | $28 million |
| Activella (estradiol / norethindrone acetate) | under 0.1% | Tier 1 | $113 thousand |
| Actos (pioglitazone) | under 0.1% | Tier 1 | $650 thousand |
| Acular (ketorolac tromethamine) | under 0.1% | Tier 1 | $44 thousand |
| Acyclovir | 100% | Tier 2 | $37 million |
| Adacel (Tdap vaccine) | 100% | Tier 1 | $16 million |
| Adalimumab-aacf | 0.3% | Tier 3 | no 2024 match |
| Adalimumab-aaty | 27.7% | Tier 5 | no 2024 match |
| Adalimumab-adaz | 17.5% | Tier 5 | $474 thousand |
| Adalimumab-adbm | 36.2% | Tier 5 | $838 thousand |
| Adalimumab-bwwd | 25.3% | Tier 5 | no 2024 match |
| Adalimumab-fkjp | 0.3% | Tier 3 | $32 thousand |
| Adalimumab-ryvk | 0.5% | Tier 5 | no 2024 match |
Show the other 168 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Adapalene | 48.8% | Tier 4 | $3 million |
| Adapalene / benzoyl peroxide | 6.1% | Tier 2 | $180 thousand |
| Adbry (tralokinumab-ldrm) | 7.7% | Tier 5 | $54 million |
| Adcirca (tadalafil) | under 0.1% | Tier 1 | $24 million |
| Adderall | under 0.1% | Tier 1 | $21 million |
| Adefovir dipivoxil | 97.4% | Tier 4 | $2 million |
| Adempas (riociguat) | 100% | Tier 5 | $694 million |
| Admelog (insulin lispro) | 12.6% | Tier 3 | $44 million |
| Advair (fluticasone propionate / salmeterol) | 65.5% | Tier 3 | $392 million |
| Afinitor (everolimus) | 0.2% | Tier 1 | $18 million |
| Agamree (vamorolone) | 0.4% | Tier 5 | $699 thousand |
| Agrylin (anagrelide) | under 0.1% | Tier 1 | $159 thousand |
| Aimovig (erenumab-aooe) | 79.2% | Tier 3 | $306 million |
| Airsupra (albuterol / budesonide) | 70.1% | Tier 3 | $25 million |
| Ajovy (fremanezumab-vfrm) | 2.7% | Tier 3 | $103 million |
| Akeega (abiraterone acetate / niraparib) | 100% | Tier 5 | $6 million |
| Aklief (trifarotene) | 0.2% | Tier 4 | $260 thousand |
| Ala-Cort (hydrocortisone) | 74% | Tier 2 | $9 thousand |
| Ala-Scalp (hydrocortisone) | 0.6% | Tier 1 | $143 thousand |
| Albendazole | 100% | Tier 4 | $6 million |
| Albuterol | 100% | Tier 2 | $10 million |
| Albuterol / ipratropium bromide | 100% | Tier 2 | no 2024 match |
| Alclometasone dipropionate | 79.8% | Tier 2 | $2 million |
| Aldactone (spironolactone) | under 0.1% | Tier 1 | $429 thousand |
| Alecensa (alectinib) | 100% | Tier 5 | $247 million |
| Alendronic acid | 100% | Tier 1 | $77 million |
| Alfuzosin hydrochloride | 100% | Tier 2 | $24 million |
| Aliskiren | 100% | Tier 4 | $9 million |
| Allopurinol | 100% | Tier 1 | $96 million |
| Almotriptan | 2% | Tier 4 | $2 million |
| Alogliptin | 1.5% | Tier 1 | $15 million |
| Alogliptin / metformin hydrochloride | 1.5% | Tier 1 | $1 million |
| Alogliptin / pioglitazone | 1.5% | Tier 1 | $410 thousand |
| Alosetron | 100% | Tier 4 | $9 million |
| Alphagan (brimonidine tartrate) | 25.2% | Tier 3 | no 2024 match |
| Alprazolam | 98.6% | Tier 2 | $64 million |
| Alrex (loteprednol etabonate) | 0.2% | Tier 3 | $6 million |
| Altavera (ethinyl estradiol / levonorgestrel) | 95.7% | Tier 2 | $65 thousand |
| Altreno (tretinoin) | 5.1% | Tier 4 | $92 thousand |
| Alunbrig (brigatinib) | 100% | Tier 5 | $42 million |
| Alvaiz (eltrombopag) | 31.2% | Tier 5 | $8 million |
| Alvesco (ciclesonide) | 32% | Tier 4 | $35 million |
| Alyacen (ethinyl estradiol / norethindrone) | 94.2% | Tier 2 | $101 thousand |
| Alyftrek (deutivacaftor / tezacaftor / vanzacaftor) | 24% | Tier 5 | no 2024 match |
| Alyq (tadalafil) | 65.5% | Tier 5 | $684 thousand |
| Amantadine hydrochloride | 100% | Tier 2 | $23 million |
| AmBisome (amphotericin b liposomal) | 4.6% | Tier 5 | $939 thousand |
| Ambrisentan | 97.1% | Tier 5 | $185 million |
| Amcinonide | 3.1% | Tier 4 | $4 million |
| Amikacin | 100% | Tier 4 | $1 million |
| Amiloride hydrochloride | 100% | Tier 2 | $2 million |
| Amiloride hydrochloride / hydrochlorothiazide | 99.1% | Tier 2 | $1 million |
| Amiodarone hydrochloride | 100% | Tier 1 | $74 million |
| Amitriptyline hydrochloride | 100% | Tier 2 | $55 million |
| Amitriptyline hydrochloride / chlordiazepoxide | 6.5% | Tier 4 | $247 thousand |
| Amitriptyline hydrochloride / perphenazine | 32.6% | Tier 2 | $439 thousand |
| Amjevita (adalimumab-atto) | 2.8% | Tier 5 | $43 million |
| Amlodipine | 100% | Tier 1 | $316 million |
| Amlodipine / atorvastatin | 82.7% | Tier 1 | $18 million |
| Amlodipine / benazepril hydrochloride | 100% | Tier 1 | no 2024 match |
| Amlodipine / hydrochlorothiazide / olmesartan medoxomil | 88.8% | Tier 1 | $18 million |
| Amlodipine / hydrochlorothiazide / valsartan | 58.8% | Tier 1 | $11 million |
| Amlodipine / olmesartan medoxomil | 90.8% | Tier 1 | no 2024 match |
| Amlodipine / telmisartan | 80.1% | Tier 1 | $4 million |
| Amlodipine / valsartan | 95.9% | Tier 1 | $23 million |
| Ammonium lactate | 100% | Tier 2 | $27 million |
| Amnesteem (isotretinoin) | 92.2% | Tier 4 | $221 thousand |
| Amoxapine | 100% | Tier 3 | $187 thousand |
| Amoxicillin | 100% | Tier 1 | $29 million |
| Amoxicillin / clavulanate | 100% | Tier 2 | $74 million |
| Amphetamine | 1.7% | Tier 4 | no 2024 match |
| Amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate | 100% | Tier 3 | $89 million |
| Amphetamine sulfate | 0.6% | Tier 4 | $128 thousand |
| Amphotericin b | 100% | Tier 4 | $2 million |
| Amphotericin b liposomal | 100% | Tier 5 | no 2024 match |
| Ampicillin | 100% | Tier 2 | $6 million |
| Ampicillin / sulbactam | 100% | Tier 4 | $3 million |
| Ampyra (dalfampridine) | 0.3% | Tier 5 | $40 million |
| Amrix (cyclobenzaprine hydrochloride) | under 0.1% | Tier 4 | $448 thousand |
| Anagrelide | 100% | Tier 3 | $5 million |
| Anastrozole | 100% | Tier 1 | $32 million |
| Andembry (garadacimab-gxii) | 3% | Tier 5 | no 2024 match |
| Angeliq (drospirenone / estradiol) | 0.8% | Tier 4 | $404 thousand |
| Annovera (ethinyl estradiol / segesterone acetate) | 0.8% | Tier 4 | $90 thousand |
| Anoro (umeclidinium / vilanterol) | 78.3% | Tier 3 | $819 million |
| Anusol HC (hydrocortisone) | under 0.1% | Tier 1 | $25 thousand |
| Anzupgo (delgocitinib) | 3.8% | Tier 5 | no 2024 match |
| Apidra (insulin glulisine, human) | 0.2% | Tier 4 | $3 million |
| Aplenzin (bupropion hydrobromide) | 3.9% | Tier 5 | $24 million |
| Apokyn (apomorphine hydrochloride) | 0.6% | Tier 5 | $70 million |
| Apomorphine hydrochloride | 30.1% | Tier 5 | $191 thousand |
| Apraclonidine | 43.4% | Tier 2 | $337 thousand |
| Aprepitant | 100% | Tier 4 | $8 million |
| Apri (desogestrel / ethinyl estradiol) | 97.5% | Tier 2 | $135 thousand |
| Apriso (mesalamine) | under 0.1% | Tier 1 | $5 million |
| Aptiom (eslicarbazepine acetate) | 27.8% | Tier 5 | $144 million |
| Aptivus (tipranavir) | 100% | Tier 5 | $1 million |
| Aqneursa (levacetylleucine) | 4% | Tier 5 | no 2024 match |
| Aqvesme (mitapivat) | 0.4% | Tier 5 | no 2024 match |
| Aralast (alpha 1-proteinase inhibitor, human) | 17.5% | Tier 5 | no 2024 match |
| Aranelle 28 (ethinyl estradiol / norethindrone) | 92.9% | Tier 2 | no 2024 match |
| Aranesp (darbepoetin alfa) | 27% | Tier 4 | $63 million |
| Arazlo (tazarotene) | 0.4% | Tier 4 | $352 thousand |
| Arcalyst (rilonacept) | 96.4% | Tier 5 | $53 million |
| Arexvy (RSV vaccine) | 100% | Tier 1 | $774 million |
| Arformoterol | 61.6% | Tier 4 | $5 million |
| Aricept (donepezil hydrochloride) | under 0.1% | Tier 1 | $1 million |
| Arikayce (amikacin liposomal) | 100% | Tier 5 | $187 million |
| Arimidex (anastrozole) | under 0.1% | Tier 1 | $4 million |
| Aripiprazole | 100% | Tier 2 | $253 million |
| Aristada (aripiprazole lauroxil) | 94.2% | Tier 5 | $269 million |
| Armodafinil | 80.3% | Tier 4 | $9 million |
| Arnuity (fluticasone furoate) | 92.1% | Tier 3 | $200 million |
| Aromasin (exemestane) | under 0.1% | Tier 1 | $1 million |
| Arthrotec (diclofenac sodium / misoprostol) | under 0.1% | Tier 1 | $638 thousand |
| Ascomp (aspirin / butalbital / caffeine / codeine phosphate) | 2.6% | Tier 4 | no 2024 match |
| Ascorbic acid and 5 more ingredients | 11.8% | Tier 2 | no 2024 match |
| Asenapine | 100% | Tier 4 | $18 million |
| Ashlyna (ethinyl estradiol) | 71.9% | Tier 2 | $60 thousand |
| Asmanex (mometasone furoate) | 19.7% | Tier 3 | $11 million |
| Aspirin / butalbital / caffeine | 26.4% | Tier 3 | $2 million |
| Aspirin / butalbital / caffeine / codeine phosphate | 3.1% | Tier 2 | no 2024 match |
| Aspirin / dipyridamole | 81.9% | Tier 4 | $17 million |
| Astagraf (tacrolimus) | 53.1% | Tier 4 | $498 thousand |
| Atacand (candesartan cilexetil) | under 0.1% | Tier 1 | $2 million |
| Atacand HCT (candesartan cilexetil / hydrochlorothiazide) | under 0.1% | Tier 1 | $512 thousand |
| Atazanavir | 100% | Tier 4 | $4 million |
| Atelvia (risedronate sodium) | under 0.1% | Tier 1 | $172 thousand |
| Atenolol | 100% | Tier 1 | $50 million |
| Atenolol / chlorthalidone | 99.8% | Tier 1 | $9 million |
| Atomoxetine | 100% | Tier 4 | $33 million |
| Atorvastatin | 100% | Tier 1 | $756 million |
| Atovaquone | 100% | Tier 4 | $41 million |
| Atovaquone / proguanil hydrochloride | 100% | Tier 4 | $7 million |
| Atropine sulfate | 99% | Tier 3 | $9 million |
| Atropine sulfate / diphenoxylate hydrochloride | 99.4% | Tier 4 | no 2024 match |
| Atrovent (ipratropium bromide) | 96% | Tier 4 | $115 million |
| Attruby (acoramidis) | 13.7% | Tier 5 | $870 thousand |
| Aubra (ethinyl estradiol / levonorgestrel) | 92.9% | Tier 2 | no 2024 match |
| Augmented betamethasone | 100% | Tier 2 | no 2024 match |
| Augmentin (amoxicillin / clavulanate) | 9.7% | Tier 4 | $126 thousand |
| Augtyro (repotrectinib) | 100% | Tier 5 | $10 million |
| Austedo (deutetrabenazine) | 89.2% | Tier 5 | $1.7 billion |
| Auvelity (bupropion hydrochloride / dextromethorphan hydrobromide) | 100% | Tier 5 | $77 million |
| Auvi-Q (epinephrine) | 19.5% | Tier 3 | $713 thousand |
| Avalide (hydrochlorothiazide / irbesartan) | under 0.1% | Tier 1 | $730 thousand |
| Avapro (irbesartan) | under 0.1% | Tier 1 | $2 million |
| Aveed (testosterone undecanoate) | 0.2% | Tier 4 | $2 million |
| Aviane 28 (ethinyl estradiol / levonorgestrel) | 98.2% | Tier 2 | no 2024 match |
| Avmapki (avutometinib) | 100% | Tier 5 | no 2024 match |
| Avonex (interferon beta-1a) | 20.1% | Tier 5 | $288 million |
| Avycaz (avibactam / ceftazidime) | 1.3% | Tier 5 | $20 million |
| Ayvakit (avapritinib) | 100% | Tier 5 | $160 million |
| Azactam (aztreonam) | under 0.1% | Tier 1 | $107 thousand |
| Azasan (azathioprine) | 4.2% | Tier 4 | $64 thousand |
| AzaSite (azithromycin) | 8.2% | Tier 4 | $2 million |
| Azathioprine | 100% | Tier 2 | $20 million |
| Azelaic acid | 73.6% | Tier 4 | $8 million |
| Azelastine hydrochloride | 100% | Tier 2 | $86 million |
| Azelastine hydrochloride / fluticasone propionate | 3.5% | Tier 4 | $18 million |
| Azelex (azelaic acid) | 3.2% | Tier 4 | $1 million |
| Azilect (rasagiline) | under 0.1% | Tier 1 | $1 million |
| Azithromycin | 100% | Tier 1 | $46 million |
| Azopt (brinzolamide) | 0.9% | Tier 3 | $14 million |
| Azor (amlodipine / olmesartan medoxomil) | under 0.1% | Tier 1 | $3 million |
| Aztreonam | 100% | Tier 4 | $2 million |
| Azulfidine (sulfasalazine) | under 0.1% | Tier 1 | $232 thousand |
| Azurette (desogestrel / ethinyl estradiol) | 95.2% | Tier 2 | $26 thousand |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans